News
An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
10d
MedPage Today on MSNMRI Leaves Man in Critical Condition; Dexcom Recall After 56 Injuries; Drug DenialsNote that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...
The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...
Reddit is surging with advertiser demand; not everyone is Substack material; and Trump released his AI Action Plan.
Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
A High Rate of Prescriptions Are Written. The Report examined the number of prescriptions that resulted from patient participation in a Program, concluding that the rate was “high”. In one case, the ...
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.
US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth platforms could violate federal anti-kickback laws. The four ...
In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:LLY), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results